Related Experiment Videos
Multinational study of pneumococcal serotypes causing acute otitis media in children
William P Hausdorff1, Greg Yothers, Ron Dagan
1Wyeth Vaccines, West Henrietta, NY 14586, USA. Hausdowp@wyeth.com
The Pediatric Infectious Disease Journal
|November 21, 2002
Summary
A limited number of Streptococcus pneumoniae serotypes, primarily those in the 7-valent pneumococcal conjugate vaccine (PCV-7), cause most acute otitis media (AOM) in young children. Serotype importance varies by age group.
Area of Science:
- Pediatrics
- Infectious Diseases
- Microbiology
Background:
- Streptococcus pneumoniae is a leading cause of acute otitis media (AOM) in young children.
- Over 90 pneumococcal serotypes exist, but their specific roles in AOM are not fully understood.
- Understanding serotype distribution is crucial for vaccine development and public health strategies.
Purpose of the Study:
- To analyze the distribution of pneumococcal serotypes causing AOM across diverse geographic regions.
- To determine the relative importance of different serotypes in children of various age groups.
- To assess the coverage of the 7-valent pneumococcal conjugate vaccine (PCV-7) against AOM-causing serotypes.
Main Methods:
- Analysis of nine datasets including 3,232 children with AOM from 1994-2000.
- Examination of pneumococcal isolates from middle ear fluid across multiple countries.
- Investigation of serotype distribution concerning age, gender, antibiotic resistance, and culture source.
Main Results:
- Serotypes 19F and 23F were most prevalent, followed by 14 and 6B.
- PCV-7 serotypes covered 60-70% of isolates in children aged 6-59 months.
- Serotypes 1, 3, and 5 showed increased importance in younger (<6 months) and older (>/=60 months) children; 4 serotypes (23F, 19F, 14, 6B) accounted for 83% of penicillin-resistant isolates.
Conclusions:
- A small group of serotypes, largely included in PCV-7, are responsible for most AOM cases in children aged 6-59 months.
- Specific serotypes are more prevalent in infants (<6 months) and older children (>/=60 months).
- Findings support the impact of PCV-7 but highlight the need to consider age-specific serotype prevalence for future vaccine strategies.